Teknova Affirms Commitment to Customer-centric Innovation with Appointment of Neal Goodwin as Chief Scientific Officer

Expanded R&D and product development support to help therapeutics developers get to market faster

Hollister, CA – 14 Jan 2021. Teknova—a leading manufacturer of cell culture media and supplements, purification buffers, and molecular biology reagents—welcomes Dr Neal Goodwin as Chief Scientific Officer (CSO). Neal brings 20 years’ experience in biotechnology and therapeutics, with tenures including CSO of Machavert Pharmaceuticals, Vice President of Corporate Research Development for Champions Oncology (NASDAQ: CSBR) and co-founder and former CSO of ProNAi Therapeutics (now Sierra Oncology; NASDAQ: SRRA). As CSO at Teknova, Neal will expand the company’s research and development capabilities and lead market outreach for innovative products, driving growth in emerging markets and providing greater product development support to customers in the therapeutics sector.

“I’m excited to join Teknova at this moment in the company’s growth” Goodwin said. “Teknova is a unique and incredibly nimble company able to respond quickly to customer needs and develop, manufacture, and ship custom GMP products at unprecedented speed”. Since the appointment of Stephen Gunstream as CEO at the end of 2019, Teknova has been rapidly enhancing its support for the therapeutics sector, and a vital part of that is having a world-class R&D department. “I’m delighted to be leading the charge in this area and look forward to developing best-in-class solutions for our customers and driving Teknova’s expansion in exciting emerging markets such as cell and gene therapies,” Goodwin added.

On Goodwin’s appointment, Gunstream said, “We’re delighted to have Neal join us as CSO. At Teknova, we keep our focus firmly on our customers’ needs. A strong R&D department is crucial to be able to quickly respond with the innovative products and the right support as our customers progress from R&D, through product development, to commercialization. Essentially, we are a partner that handles reagent optimization to deliver GMP products manufactured to specific needs, enabling our customers to focus on getting their products to market as quickly as possible. Neal’s wealth of experience in this area will be of tremendous benefit to the company and all our customers.”

To learn more about Teknova, visit www.teknova.com.  

About Teknova

Founded in 1996, Teknova has established itself as a leader in providing critical reagents for bioprocessing, bioproduction, and molecular diagnostics. Product offerings include cell culture media and supplements, protein purification buffers, and molecular biology reagents for the life sciences and healthcare communities. Teknova prides itself on its agility and customer centricity, allowing the company to meet the most complex formulation and packaging requirements at unprecedented delivery times. Teknova supports customers in the research, clinical, and applied markets with custom and specialty products beyond standard catalog offerings, delivering cost savings for research and development, diagnostics, and production of therapeutics.

Find out more at www.teknova.com.

Contact:
Alto Marketing:
Victoria Coupe – Senior Account Manager; E: victoriac@alto-marketing.com; T: +44(0)1489 557672

Teknova: 
Nicola Brookman-Amissah – Director, Marketing; E: nicola.brookman@teknova.com; T: +1 (831) 291-5409

All Topics